Cambridge Acquisition Corp., a SPAC formed in late 2025, reported in its May 2026 10-Q a robust balance sheet with approximately $1.1 billion in current assets against minimal liabilities, reflecting its trust account holding IPO proceeds for acquisitions. Since March 2026, the components of its units—Class A Ordinary Shares and redeemable warrants—have traded separately, enhancing liquidity dynamics. The company leverages an experienced management team focused on harm-reduction, wellness, and technology platforms to identify high-growth targets primarily in the U.S. and Europe. Key risks include geopolitical tensions impacting markets and compliance with Nasdaq deadlines for consummating a deal. Near-term milestones depend on announcements of initial Business Combination talks and investor response to the separate trading of securities.